Related references
Note: Only part of the references are listed.PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8(+) T-Cell-Driven Antitumor Immunity
Sarah L. Buchan et al.
CLINICAL CANCER RESEARCH (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
Karen O. Dixon et al.
JOURNAL OF IMMUNOLOGY (2018)
A Believer's Overview of Cancer Immunosurveillance and Immunotherapy
Olivera J. Finn
JOURNAL OF IMMUNOLOGY (2018)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
Alfred L. Garfall et al.
JCI INSIGHT (2018)
Antigen-mediated regulation in monoclonal gammopathies and myeloma
Shiny Nair et al.
JCI INSIGHT (2018)
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Sarah L. Buchan et al.
BLOOD (2018)
PD-1 regulates KLRG1+ group 2 innate lymphoid cells
Samuel Taylor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma
Caterina Musolino et al.
MEDIATORS OF INFLAMMATION (2017)
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
Federica Costa et al.
ONCOTARGET (2017)
Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy
Jithendra Kini Bailur et al.
BLOOD ADVANCES (2017)
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Ashraf Badros et al.
BLOOD (2017)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An et al.
BLOOD (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2016)
Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
H. Suen et al.
LEUKEMIA (2016)
Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis
Christoph S. N. Klose et al.
NATURE IMMUNOLOGY (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma
Shiny Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7
Matthew M. Halpert et al.
STEM CELLS AND DEVELOPMENT (2016)
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival
C. Botta et al.
BLOOD CANCER JOURNAL (2016)
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells
Chandra Sekhar Boddupalli et al.
JCI INSIGHT (2016)
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy
Madhav V. Dhodapkar et al.
BLOOD (2015)
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Kartik Sehgal et al.
BLOOD (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
Michele Maio et al.
CLINICAL CANCER RESEARCH (2015)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Guellue Goerguen et al.
CLINICAL CANCER RESEARCH (2015)
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Camille Guillerey et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
H. Suen et al.
LEUKEMIA (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
Yago Pico de Coana et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
S. Yousef et al.
BLOOD CANCER JOURNAL (2015)
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
Barbara Castella et al.
ONCOIMMUNOLOGY (2015)
Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation
Shiny Nair et al.
BLOOD (2015)
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
Anne-Marit Sponaas et al.
PLOS ONE (2015)
Immune modulation for cancer therapy
J. Naidoo et al.
BRITISH JOURNAL OF CANCER (2014)
Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers
Jennifer A. Westwood et al.
LEUKEMIA RESEARCH (2014)
Immunological Dysregulation in Multiple Myeloma Microenvironment
Alessandra Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Lenalidomide induces degradation of IKZF1 and IKZF3
Jan Kroenke et al.
ONCOIMMUNOLOGY (2014)
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
Joshua Richter et al.
BLOOD (2013)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Guellue Topal Goerguen et al.
BLOOD (2013)
Lenalidomide enhances anti-myeloma cellular immunity
Katarina Luptakova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Pathogenesis of Myeloma
Kenneth C. Anderson et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
William H. D. Hallett et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges
Madhav V. Dhodapkar et al.
CLINICAL IMMUNOLOGY (2011)
Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro
Marco Tucci et al.
EXPERIMENTAL HEMATOLOGY (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?
Marco Tucci et al.
ONCOLOGIST (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Ikaros Silences T-bet Expression and Interferon-γ Production during T Helper 2 Differentiation
Rajan M. Thomas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Hyun-Tak Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma
M. K. Brimnes et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2010)
Regulation of multiple myeloma survival and progression by CD1d
Emmanouil Spanoudakis et al.
BLOOD (2009)
MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2
Grazia Maria Spaggiari et al.
BLOOD (2009)
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease
Anjli Kukreja et al.
BLOOD (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Christine Galustian et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer
David H. Chang et al.
BLOOD (2008)
Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma
Kavita M. Dhodapkar et al.
BLOOD (2008)
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Oihana Murillo et al.
CLINICAL CANCER RESEARCH (2008)
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Jedd D. Wolchok et al.
ONCOLOGIST (2008)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes
Rajan M. Thomas et al.
JOURNAL OF IMMUNOLOGY (2007)
Body mass index and risk of multiple myeloma: A meta-analysis
Susanna C. Larsson et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Hnmunomodulatory properties of mesenchymal stromal cells
Alma J. Nauta et al.
BLOOD (2007)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Nizar J. Bahlis et al.
BLOOD (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Anjli Kukreja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
John J. Engelhardt et al.
JOURNAL OF IMMUNOLOGY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Harnessing host immune responses to preneoplasia: promise and challenges
MV Dhodapkar
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes
HD Dong et al.
IMMUNITY (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
M Ratta et al.
BLOOD (2002)
T-cell regulation by CD28 and CTLA-4
ML Alegre et al.
NATURE REVIEWS IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
